MT Newswires
European Equities Traded in the US as American Depositary Receipts Fall in Tuesday Trading
📉
AI Sentiment
Negative
3/10
- Home
- BCYC
as of 01-22-2026 3:40pm EST
$7.24
+$0.34
+4.93%
Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops that stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical needs. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC. The company has two segments: the United Kingdom and the United States. It derives maximum revenue from United States.
| Founded: | 2009 | Country: | United Kingdom |
| Employees: | N/A | City: | CAMBRIDGE |
| Market Cap: | 476.6M | IPO Year: | 2019 |
| Target Price: | $18.73 | AVG Volume (30 days): | 241.1K |
| Analyst Decision: | Buy | Number of Analysts: | 11 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.62 | EPS Growth: | N/A |
| 52 Week Low/High: | $6.03 - $13.90 | Next Earning Date: | 02-24-2026 |
| Revenue: | $28,339,000 | Revenue Growth: | -23.20% |
| Revenue Growth (this year): | -6.3% | Revenue Growth (next year): | -4.86% |
AI-Powered BCYC Daily Prediction
Machine learning model trained on 25+ technical indicators
Updated a day ago
AI Recommendation
hold
Model Accuracy: 0.00%
0.00%
Confidence
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Bicycle Therapeutics plc (BCYC)
Skynner Michael
Sell
CHIEF TECHNOLOGY OFFICER
BCYC Jan 5, 2026
Avg Cost/Share
$6.46
Shares
3,266
Total Value
$21,098.36
Owned After
161,966
SEC Form 4
Hannay Michael Charles Ferguson
Sell
CHIEF PROD & SUPPLY CHAIN OFF
BCYC Jan 5, 2026
Avg Cost/Share
$6.45
Shares
2,367
Total Value
$15,267.15
Owned After
97,908
SEC Form 4
Thompson Travis Alvin
Sell
CHIEF ACCOUNTING OFFICER
BCYC Jan 5, 2026
Avg Cost/Share
$6.45
Shares
1,115
Total Value
$7,191.75
Owned After
66,265
SEC Form 4
Young Alethia
Sell
Chief Financial Officer
BCYC Jan 5, 2026
Avg Cost/Share
$6.50
Shares
4,334
Total Value
$28,123.32
Owned After
88,959
Milnes Alistair
Sell
CHIEF OPERATING OFFICER
BCYC Jan 5, 2026
Avg Cost/Share
$6.46
Shares
3,416
Total Value
$22,067.36
Owned After
136,717
SEC Form 4
Skynner Michael
Sell
CHIEF TECHNOLOGY OFFICER
BCYC Jan 2, 2026
Avg Cost/Share
$6.80
Shares
3,045
Total Value
$20,706.00
Owned After
161,966
SEC Form 4
Hannay Michael Charles Ferguson
Sell
CHIEF PROD & SUPPLY CHAIN OFF
BCYC Jan 2, 2026
Avg Cost/Share
$6.80
Shares
2,827
Total Value
$19,223.60
Owned After
97,908
SEC Form 4
Thompson Travis Alvin
Sell
CHIEF ACCOUNTING OFFICER
BCYC Jan 2, 2026
Avg Cost/Share
$6.80
Shares
1,317
Total Value
$8,955.60
Owned After
66,265
SEC Form 4
Young Alethia
Sell
Chief Financial Officer
BCYC Jan 2, 2026
Avg Cost/Share
$6.80
Shares
3,289
Total Value
$22,365.20
Owned After
88,959
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Skynner Michael | BCYC | CHIEF TECHNOLOGY OFFICER | Jan 5, 2026 | Sell | $6.46 | 3,266 | $21,098.36 | 161,966 | |
| Hannay Michael Charles Ferguson | BCYC | CHIEF PROD & SUPPLY CHAIN OFF | Jan 5, 2026 | Sell | $6.45 | 2,367 | $15,267.15 | 97,908 | |
| Thompson Travis Alvin | BCYC | CHIEF ACCOUNTING OFFICER | Jan 5, 2026 | Sell | $6.45 | 1,115 | $7,191.75 | 66,265 | |
| Young Alethia | BCYC | Chief Financial Officer | Jan 5, 2026 | Sell | $6.50 | 4,334 | $28,123.32 | 88,959 | |
| Milnes Alistair | BCYC | CHIEF OPERATING OFFICER | Jan 5, 2026 | Sell | $6.46 | 3,416 | $22,067.36 | 136,717 | |
| Lee Kevin | BCYC | CHIEF EXECUTIVE OFFICER | Jan 5, 2026 | Sell | $6.46 | 10,989 | $70,988.94 | 618,996 | |
| Skynner Michael | BCYC | CHIEF TECHNOLOGY OFFICER | Jan 2, 2026 | Sell | $6.80 | 3,045 | $20,706.00 | 161,966 | |
| Hannay Michael Charles Ferguson | BCYC | CHIEF PROD & SUPPLY CHAIN OFF | Jan 2, 2026 | Sell | $6.80 | 2,827 | $19,223.60 | 97,908 | |
| Thompson Travis Alvin | BCYC | CHIEF ACCOUNTING OFFICER | Jan 2, 2026 | Sell | $6.80 | 1,317 | $8,955.60 | 66,265 | |
| Young Alethia | BCYC | Chief Financial Officer | Jan 2, 2026 | Sell | $6.80 | 3,289 | $22,365.20 | 88,959 |
Latest Bicycle Therapeutics plc News
BCYC Breaking Stock News: Dive into BCYC Ticker-Specific Updates for Smart Investing
Compare BCYC vs Leading Stocks
See how BCYC stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "BCYC Bicycle Therapeutics plc - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.